ArticleFrontiers in immunology2026
Crosstalk of cancer stemness-neutrophils in outcome of intracranial germ cell tumors.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intracranial germ cell tumors (iGCTs) are categorized into germinomas (GEs) and non-germinomatous germ cell tumors (NGGCTs), which show divergent clinical outcomes with GEs having a significantly more favorable prognosis. This prognostic disparity suggests distinct biological characteristics, yet the association between tumor stemness and the host immune microenvironment, particularly in pre-treatment peripheral blood, remains poorly understood. Therefore, this study integrated multi-omics data, immune cell enrichment scores, and peripheral blood analyses to elucidate the relationship between cancer stemness indices and immune cells, especially neutrophils; and to evaluate its prognosis and treatment strategy in iGCTs. Methods: We included iGCT patients from Tiantan Hospital, all of whom underwent peripheral blood testing before pre-chemotherapy. In addition, gene expression microarray, 450K methylation data, and copy number variation data were obtained from the Gene Expression Omnibus (GEO) database. Bioinformatics analysis was used to assess and compare stemness, biological functions, immune microenvironment characteristics between GEs and NGGCTs. Furthermore, we specifically investigated the correlation between stemness indices and neutrophil levels in both subtypes. Results: Our analysis revealed that the stemness of GEs was significantly higher than that of NGGCTs. Functional enrichment analysis indicated that GEs are primarily involved in processes related to cell proliferation, whereas NGGCTs were mainly associated with extracellular matrix processes. Patients with GEs had better prognoses than those with NGGCTs, highlighting the crucial role of the tumor microenvironment on tumor progression. The immune landscape also differed substantially between the two subtypes, with distinct patterns of immune cell infiltration and response. Notably, the correlation between cancer stemness and neutrophil levels showed the most marked difference between GEs and NGGCTs. Our data further validated that neutrophil abundance is positively associated with increased malignancy in iGCTs, suggesting that neutrophils represent a key factor influencing iGCT outcomes. Conclusion: Our study demonstrates that the interaction between neutrophils and stemness contributes to the malignant progression of iGCTs, leading to adverse clinical outcomes. These findings not only advance our understanding of iGCT biology but also highlight potential novel therapeutic targets. Moreover, they provide a rationale for developing immunotherapy strategies aimed at modulating the neutrophil-stemness axis in iGCTs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.